Literature DB >> 23522923

The need for proportionate regulation of clinical trials.

Pamela Kearns1.   

Abstract

Mesh：

Year:  2013        PMID： 23522923     DOI： 10.1016/S1470-2045(13)70077-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  A pilot test of the new Swiss regulatory procedure for categorizing clinical trials by risk: A randomized controlled trial.

Authors:  Myriam Cevallos; Stephanie Züllig; Andri Christen; Brigitte E Meier; Martin Goetz; Michael Coslovsky; Sven Trelle
Journal:  Clin Trials       Date:  2015-06-29       Impact factor: 2.486

2.  Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.

Authors:  Wolfgang E Berdel
Journal:  Cancers (Basel)       Date:  2022-03-03       Impact factor: 6.639

3.  Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda.

Authors:  Gilles Vassal; Edel Fitzgerald; Martin Schrappe; Frédéric Arnold; Jerzy Kowalczyk; David Walker; Lars Hjorth; Riccardo Riccardi; Anita Kienesberger; Kathy-Pritchard Jones; Maria Grazia Valsecchi; Dragana Janic; Henrik Hasle; Pamela Kearns; Giulia Petrarulo; Francesco Florindi; Samira Essiaf; Ruth Ladenstein
Journal:  Pediatr Blood Cancer       Date:  2014-04-07       Impact factor: 3.167

4.  New clinical trials regulation in Spain: analysis of royal decree 1090/2015.

Authors:  M Martin Jimenez; A Calvo Ferrandiz; J Aparicio Urtasun; R Garcia-Campelo; E Gonzalez-Flores; M Lazaro Quintela; M Muñoz Mateu; C A Rodriguez Sanchez; A Santaballa Bertran; J M Sepulveda Sanchez; R Vera Garcia; J A Virizuela Echaburu; M A Segui Palmer
Journal:  Clin Transl Oncol       Date:  2016-10-07       Impact factor: 3.405
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.